MAINZ, Germany, October 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced it had commenced its public exchange offer (the “Offer”) for all outstanding shares of CureVac N.V. (Nasdaq: CVAC, “CureVac”). The Offer is being made pursuant to the previously announced purchase agreement between BioNTech and CureVac, dated as of June 12, 2025 (the “Purchase Agreement”)...
Moderna and BioNTech were the main 'saviors' of people and economies from COVID-19. However, since the pandemic ended, their stock prices have fallen by more than 70%. Recognizing this, BioNTech and Moderna continue to actively diversify their portfolios of experimental drugs and vaccines toward cancer treatment.
Europa bringt erfolgreiche Unternehmen hervor, doch oft ziehen sie die USA für einen Börsengang vor - wie der Mainzer Impfstoffentwickler Biontech US09075V1026 oder der Bezahldienst Klarna GB00BMHVL512.
On Sept. 30, Pfizer announced a deal with the U.S. government that will allow the pharmaceutical leader to avoid President Donald Trump's tariffs for three years in exchange for slashing the prices of certain drugs in the U.S. and investing in local manufacturing efforts. This deal lifted not only Pfizer, but also much of the healthcare sector, especially the company's drugmaking peers, as Wall...
BioNTech SE, InstaDeep Ltd - Special Call Company Participants Ugur Sahin - Co-Founder, CEO & Chair of the Management Board Karim Beguir Alexandre Laterre Bernardo Almeida Bora Guloglu Nicolas Lopez Carranza Youssef Ben Dhieb Cheng Zhang Antoine Delaunay Conference Call Participants Lexi Walls Michael Rooney Michael Pye - Baillie Gifford Overseas Limited Presentation Unknown Executive Hi. Good ...
Germany-based BioNTech (BNTX 3.64%) saw its U.S. listed stock enjoy a mini-pop on Wednesday, and for once this wasn't largely based on the Comirnaty COVID-19 vaccine it developed with Pfizer. Rather, investors seemed to be cheered by the biotech's continuing efforts to harness artificial intelligence (AI) technology.
MAINZ, Germany, September 23, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”), alongside its artificial intelligence (“AI”) company InstaDeep Ltd. (“InstaDeep”), will host its second AI Day, an edition of BioNTech's “Innovation Series”, at 09:00 a.m. EDT (3:00 p.m. CEST) on Wednesday, October 1, 2025, in London, United Kingdom. The event will provide an overview of BioNTech's AI...
A victory on the regulatory front and a bullish analyst move were the twin news items propelling BioNTech's (BNTX 2.52%) shares higher as the stock trading week began on Monday. The Germany-based biotech's equity rose by almost 3% in value during the session, comparing well to the 0.4% improvement of the S&P 500 index.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.